273 related articles for article (PubMed ID: 24399651)
1. The impact of arsenic trioxide and all-trans retinoic acid on p53 R273H-codon mutant glioblastoma.
Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
Tumour Biol; 2014 May; 35(5):4567-80. PubMed ID: 24399651
[TBL] [Abstract][Full Text] [Related]
2. Granulocyte colony-stimulating factor potentiates differentiation induction by all-trans retinoic acid and arsenic trioxide and enhances arsenic uptake in the acute promyelocytic leukemia cell line HT93A.
Iriyama N; Yuan B; Hatta Y; Horikoshi A; Yoshino Y; Toyoda H; Aizawa S; Takeuchi J
Oncol Rep; 2012 Nov; 28(5):1875-82. PubMed ID: 22940758
[TBL] [Abstract][Full Text] [Related]
3. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid.
Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M
Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261
[TBL] [Abstract][Full Text] [Related]
4. Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.
Jung YS; Cheong HJ; Kim SJ; Kim KH; Lee N; Park HS; Won JH
Leuk Res; 2014 Aug; 38(8):977-82. PubMed ID: 24953245
[TBL] [Abstract][Full Text] [Related]
5. All-trans retinoic acid and arsenic trioxide induce apoptosis and modulate intracellular concentrations of calcium in hepatocellular carcinoma cells.
Wei J; Ye C; Liu F; Wang W
J Chemother; 2014 Dec; 26(6):348-52. PubMed ID: 25068185
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells.
Martelli MP; Gionfriddo I; Mezzasoma F; Milano F; Pierangeli S; Mulas F; Pacini R; Tabarrini A; Pettirossi V; Rossi R; Vetro C; Brunetti L; Sportoletti P; Tiacci E; Di Raimondo F; Falini B
Blood; 2015 May; 125(22):3455-65. PubMed ID: 25795919
[TBL] [Abstract][Full Text] [Related]
7. Arsenic trioxide inhibits Hedgehog, Notch and stem cell properties in glioblastoma neurospheres.
Ding D; Lim KS; Eberhart CG
Acta Neuropathol Commun; 2014 Mar; 2():31. PubMed ID: 24685274
[TBL] [Abstract][Full Text] [Related]
8. Targeting of EGFR increase anti-cancer effects of arsenic trioxide: Promising treatment for glioblastoma multiform.
Mesbahi Y; Zekri A; Ahmadian S; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Eur J Pharmacol; 2018 Feb; 820():274-285. PubMed ID: 29274334
[TBL] [Abstract][Full Text] [Related]
9. Glycolytic metabolism confers resistance to combined all-trans retinoic acid and arsenic trioxide-induced apoptosis in HL60rho0 cells.
Herst PM; Hesketh EL; Ritchie DS; Berridge MV
Leuk Res; 2008 Feb; 32(2):327-33. PubMed ID: 17580091
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide Alters the MicroRNA Expression Profile of U87 glioblastoma.
Shidfar F; Ghaffari SH; Tavoosidana G; Hosseini E; Alimoghaddam K; Ghavamzadeh A
Anticancer Agents Med Chem; 2015; 16(2):247-58. PubMed ID: 26118712
[TBL] [Abstract][Full Text] [Related]
11. Increased growth-inhibitory and cytotoxic activity of arsenic trioxide in head and neck carcinoma cells with functional p53 deficiency and resistance to EGFR blockade.
Boyko-Fabian M; Niehr F; Distel L; Budach V; Tinhofer I
PLoS One; 2014; 9(6):e98867. PubMed ID: 24927258
[TBL] [Abstract][Full Text] [Related]
12. Arsenic Trioxide Induces Apoptosis and Incapacitates Proliferation and Invasive Properties of U87MG Glioblastoma Cells through a Possible NF-κB-Mediated Mechanism.
Ghaffari SH; Yousefi M; Dizaji MZ; Momeny M; Bashash D; Zekri A; Alimoghaddam K; Ghavamzadeh A
Asian Pac J Cancer Prev; 2016; 17(3):1553-64. PubMed ID: 27039805
[TBL] [Abstract][Full Text] [Related]
13. All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells.
Liu X; Chen J; Yu S; Yan L; Guo H; Dai J; Zhang W; Zhu J
Cell Death Dis; 2017 May; 8(5):e2782. PubMed ID: 28492552
[TBL] [Abstract][Full Text] [Related]
14. Apoptosis induction by (+)alpha-tocopheryl succinate in the absence or presence of all-trans retinoic acid and arsenic trioxide in NB4, NB4-R2 and primary APL cells.
Freitas RA; Silva dos Santos GA; Gimenes Teixeira HL; Scheucher PS; Lucena-Araujo AR; Lima AS; Abreu e Lima RS; Garcia AB; Jordão AA; Falcão RP; Vannucchi H; Rego EM
Leuk Res; 2009 Jul; 33(7):958-63. PubMed ID: 19013639
[TBL] [Abstract][Full Text] [Related]
15. Glioblastoma stem cells: a new target for metformin and arsenic trioxide.
Carmignani M; Volpe AR; Aldea M; Soritau O; Irimie A; Florian IS; Tomuleasa C; Baritchii A; Petrushev B; Crisan G; Valle G
J Biol Regul Homeost Agents; 2014; 28(1):1-15. PubMed ID: 24750786
[TBL] [Abstract][Full Text] [Related]
16. All-trans retinoic acid modulates cancer stem cells of glioblastoma multiforme in an MAPK-dependent manner.
Karsy M; Albert L; Tobias ME; Murali R; Jhanwar-Uniyal M
Anticancer Res; 2010 Dec; 30(12):4915-20. PubMed ID: 21187470
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide sensitizes glioblastoma to a myc inhibitor.
Yoshimura Y; Shiino A; Muraki K; Fukami T; Yamada S; Satow T; Fukuda M; Saiki M; Hojo M; Miyamoto S; Onishi N; Saya H; Inubushi T; Nozaki K; Tanigaki K
PLoS One; 2015; 10(6):e0128288. PubMed ID: 26038891
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide depletes cancer stem-like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of Notch pathway.
Wu J; Ji Z; Liu H; Liu Y; Han D; Shi C; Shi C; Wang C; Yang G; Chen X; Shen C; Li H; Bi Y; Zhang D; Zhao S
Toxicol Lett; 2013 Jun; 220(1):61-9. PubMed ID: 23542114
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
[TBL] [Abstract][Full Text] [Related]
20. Arsenic trioxide cooperates with all trans retinoic acid to enhance mitogen-activated protein kinase activation and differentiation in PML-RARalpha negative human myeloblastic leukemia cells.
Nayak S; Shen M; Bunaciu RP; Bloom SE; Varner JD; Yen A
Leuk Lymphoma; 2010 Sep; 51(9):1734-47. PubMed ID: 20615082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
